Gene-editing outfit Editas Medicine (NASDAQ:EDIT) jumps 10% premarket on average volume in response to its announcement that it has entered into an exclusive R&D alliance with Allergan (AGN) that ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果